18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging

ObjectiveThe aim of this study was to evaluate the utility of 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET/computed tomography (CT) imaging in the pretreatment evaluation of metastatic gastric cancer in comparison with 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging. MethodsA total of 39 metastatic gastric cancer patients were enrolled in the study. Attenuation-corrected whole-body 18F-FLT and 18F-FDG PET/CT (low-dose CT) imaging was performed on two consecutive days before chemotherapy. ResultsAccumulation of focal activity was visible in primary tumors on 18F-FLT PET/CT in 36/39 patients and on 18F-FDG PET/CT in 37/39 patients, with sensitivities of 92.3 and 94.9%, respectively. Further, three of the 36 FLT-avid primary tumors were almost undetected because they were covered by a high background hepatic uptake. Because of the high physiological uptake of 18F-FLT in the liver [median maximum standardized uptake value (SUVmax) 5.5, range 4.5–8.3] and the bone marrow (median SUVmax 14.8, range 10.8–22.0), the sensitivity of 18F-FLT PET/CT versus 18F-FDG PET/CT for detecting liver metastases and bone metastases was 30.0% (6/20) versus 100% (20/20) and 1/5 (20.0%) versus 5/5 (100%), respectively (P<0.05). Metabolically positive findings of lymph node, peritoneal, and ovarian metastases were similar between the two modalities: 96.8% (30/31) versus 93.5% (29/31), 89.5% (17/19) versus 94.7% (18/19), and 90.9% (10/11) versus 90.9% (10/11) of patients for 18F-FLT versus 18F-FDG, respectively (P>0.05). Conclusion 18F-FLT PET/CT imaging is not recommended for pretreatment assessment of metastatic gastric cancer as it is not competent enough to evaluate liver and bone metastases; moreover, the high background hepatic uptake may cover the gastric primary tumors located adjacent to the liver.

[1]  Mingwei Wang,et al.  Routinely automated production of 3'-deoxy-3'-[~(18)F] fluorothymidine as a specific molecular imaging probe of tumor cell proliferation , 2011 .

[2]  Y. Nishiyama,et al.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Schwaiger,et al.  Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis , 2007, Journal of Nuclear Medicine.

[4]  Hubert Vesselle,et al.  FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. , 2007, Seminars in nuclear medicine.

[5]  K. Kang,et al.  Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Mark Muzi,et al.  True tracers: comparing FDG with glucose and FLT with thymidine. , 2005, Nuclear medicine and biology.

[7]  P. Price,et al.  The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  A. Harris,et al.  Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. , 2004, Biochimica et biophysica acta.

[9]  K. Krohn,et al.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  D. Visvikis,et al.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography , 2003, Gut.

[11]  A. Shields,et al.  PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  B. Kamen,et al.  Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs , 2002, Cancer Chemotherapy and Pharmacology.

[13]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[15]  B. Dutrillaux,et al.  Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. , 1994, British Journal of Cancer.

[16]  PET Imaging with 18 F-FLT and Thymidine Analogs: Promise and Pitfalls , 2003 .

[17]  O. Muzik,et al.  Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.